• We analyzed the long-term results of high-dose cytarabine-anthracycline consolidation chemotherapy without maintenance treatment and examined the effect of major prognostic factors, including age, sex, history of preleukemia, and cytogenetics. (elsevierpure.com)
  • In June 2020, the European Commission granted marketing authorisation for Daurismo® (glasdegib), in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary AML in adult patients who are not candidates for standard induction chemotherapy. (scuba-capsule.de)
  • Forty infants have subsequently been treated on a protocol incorporating further intensification with an option for high-dose chemotherapy and autologous or allogeneic bone marrow transplantation. (nih.gov)
  • Only three of 11 children treated by high-dose chemotherapy and transplantation remain alive in remission. (nih.gov)
  • These results show the susceptibility of infants to the toxicity of intensive chemotherapy and do not support the use of short term high-dose chemotherapy alone in the management of infant leukaemia. (nih.gov)
  • Cytarabine is a key constituent of remission induction chemotherapy. (maastrichtuniversity.nl)
  • A significant survival advantage of sensitizing AML for chemotherapy with G-CSF was not apparent in the entire study group, but it was seen in patients treated with escalated-dose cytarabine during remission induction. (maastrichtuniversity.nl)
  • Treatment for primary central nervous system lymphoma requires high doses of chemotherapy that enter the central nervous system, such as high-dose methotrexate and high-dose cytarabine. (dana-farber.org)
  • Radiation therapy has been used as part of the treatment for this lymphoma in adults but may not be necessary if high dose chemotherapy is used in the treatment plan. (dana-farber.org)
  • After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible patients with AML above 65 years of age (median 70, range 66-81) were randomly assigned in this open label randomized Phase II study to receive standard chemotherapy (3+7) with or without tosedostat at the selected daily dose of 120 mg ( n = 116), days 1-21. (unige.ch)
  • Cohort 1 and Cohort 2: Prior therapy must have included: - Anthracycline or bendamustine-containing chemotherapy and - Anti-CD20 monoclonal antibody therapy and - Ibrutinib or acalabrutinib Cohort 3: Prior therapy must have included anthracycline, bendamustine-, or high dose cytarabine-containing chemotherapy and anti-CD20 monoclonal antibody therapy. (who.int)
  • Patients also receive methotrexate intrathecally (IT) on days 7 and 28 and cytarabine IT on day 0. (knowcancer.com)
  • For patients without CNS metastases, CNS prophylaxis (eg, with systemic and/or intrathecal methotrexate and/or cytarabine ) is essential. (msdmanuals.com)
  • Since the calcium folinate rescue dosage regimen depends heavily on the posology and method of the intermediate- or high-dose methotrexate administration, the methotrexate protocol will dictate the dosage regimen of calcium folinate rescue. (janusinfo.se)
  • refer to the applied intermediate or high dose methotrexate protocol for posology and method of administration of calcium folinate. (janusinfo.se)
  • Calcium folinate rescue is necessary when methotrexate is given at doses exceeding 500 mg/m2 body surface and should be considered with doses of 100 mg - 500 mg/m2 body surface. (janusinfo.se)
  • The lesions appeared 14 days after the last dose of methotrexate. (bvsalud.org)
  • This Joint Assessment aims to compare the clinical effectiveness and safety of glasdegib, in combination with low-dose cytarabine, in the target patient population with relevant comparators (azacitidine, decitabine, low-dose cytarabine, and best supportive care) according to the national requirements of EUnetHTA partners. (scuba-capsule.de)
  • However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of reduced-dose azacitidine (AZA) vs. decitabine (DAC) in adult MDS patients. (medscimonit.com)
  • In the high-dose regimen, cytarabine is given at 3 g/ m2 every 12 hours for 3 days of each cycle. (pharmacytimes.com)
  • However, patients treated with the escalated-dose cytarabine regimen benefited from G-CSF priming, with improved event-free survival (P = .01) and overall survival (P = .003), compared with patients without G-CSF undergoing escalated-dose cytarabine treatment. (maastrichtuniversity.nl)
  • In the initial part of the study, 406 patients were also randomized between 2 cytarabine regimens comparing conventional-dose (199 patients) versus escalated-dose (207 patients) cytarabine in cycles 1 and 2. (maastrichtuniversity.nl)
  • This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. (uni-luebeck.de)
  • The objective of this study is to assess the safety and tolerability, including the maximum tolerated dose, of ASP2215 in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML). (mayo.edu)
  • High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. (stembook.org)
  • E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia. (cdc.gov)
  • In the second cycle, patients received cytarabine 1000 mg/m 2 twice daily on days 1-6 with or without tosedostat. (unige.ch)
  • and cytarabine from 1.40 mg per 1000 population per day in 2010 to 0.96 in 2013. (who.int)
  • As is usual with antileukemic agents, severe myelosuppression occurs when Idamycin PFS is used at effective therapeutic doses. (medicinenet.com)
  • Involved-site radiation therapy (ISRT) is typically recommended, because high-dose, large-field radiation therapy (LFRT) increases risk for heart disease, pulmonary dysfunction, and secondary cancers. (medscape.com)
  • Calcium folinate can be administered either by the intravenous route at a dose of 20 mg/m2 for 5 to 10 minutes every 6 hours for a total daily dose of 80 mg/m2 or by oral route with four doses of 20 mg/m2 administered at equal time intervals. (janusinfo.se)
  • Idamycin PFS Injection 12 mg/m 2 daily for 3 days by slow (10 to 15 min) intravenous injection in combination with cytarabine. (medicinenet.com)
  • The cytarabine may be given as 100 mg/m 2 daily by continuous infusion for 7 days or as cytarabine 25 mg/m 2 intravenous bolus followed by cytarabine 200 mg/m 2 daily for 5 days continuous infusion. (medicinenet.com)
  • Doses of 3 mg/m(2) were associated with fewer early deaths than doses of 6 mg/m(2), with equal efficacy. (nih.gov)
  • Administration of the second course should be delayed in patients who experience severe mucositis, until recovery from this toxicity has occurred, and a dose reduction of 25% is recommended. (medicinenet.com)
  • Daily doses of calcium folinate should be adjusted depending on the hematological toxicity of trimetrexate. (janusinfo.se)
  • Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects. (venclexta.com)
  • After several parenteral doses treatment can be switched over to the oral form. (janusinfo.se)
  • Prevention: Calcium folinate should be administered every day during treatment with trimetrexate and for 72 hours after the last dose of trimetrexate. (janusinfo.se)
  • In case of high dose pyrimethamine or prolonged treatment with low doses, calcium folinate 5 to 50 mg/day should be simultaneously administered, based on the results of the peripheral blood counts. (janusinfo.se)
  • Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased. (venclexta.com)
  • and asparaginase intramuscularly (IM) on days 3, 5, and 7 and then 3 times a week for 9 doses (during days 8-21). (knowcancer.com)
  • and cytarabine IV or SC on days 28-31 and 35-38. (knowcancer.com)
  • Common side effects of Idamycin PFS include nausea, vomiting, abdominal or stomach cramps, diarrhea, headache, facial flushing during administration, eye irritation or tearing, darkening of the nail beds and skin folds, red-colored urine for 1 or 2 days following a dose, and temporary hair loss. (medicinenet.com)
  • Overdosage (possibly occurring with trimetrexate doses above 90 mg/m2 without concomitant administration of calcium folinate): after stopping trimetrexate, calcium folinate 40 mg/m2 IV every 6 hours for 3 days. (janusinfo.se)
  • It is recommended not to initiate therapy with maximum doses in these patients due to the likely increase frequency of adverse reactions. (pdr.net)
  • One hundred twenty-three patients were eligible for high-dose cytarabine-based consolidation administered in two to three courses. (elsevierpure.com)
  • Our results show an improved LFS for younger patients treated with high-dose cytarabine-based consolidation. (elsevierpure.com)
  • These interruptions contributed to errors such as wrong dose, wrong medication, omission, and medication mislabeling. (ismp.org)
  • The purpose of this study is to evaluate the rate of complete MRD response by flow cytometry after 4 weekly doses of daratumumab-hyaluronidase (Day 29) among patients with MRD positive T-ALL in hematologic morphologic complete remission or complete remission with incomplete hematologic recovery. (mayo.edu)
  • Administration of low-dose cytarabine results in immediate S-phase arrest and subsequent activation of cell cycling in murine stem cells. (rug.nl)